XW143G8Transfusion of Atidarsagene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8

New Technology›Anatomical Regions›Transfusion
  • Billable / Specific Code
ICD-10-PCS XW143G8
CMS Source: FY 2027 ICD-10-PCS dataset. Effective Oct 1, 2026 – Sep 30, 2027.FacebookXLinkedInPrint

XW143G8 is a billable ICD-10-PCS procedure code for Transfusion of Atidarsagene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRGs 016, 017. The root operation Transfusion involves putting in blood or blood products. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Administration and transfusion of bone marrow, stem cells, pancreatic islet cells, and t-cells.

Code Identity

ICD-10-PCS Code
XW143G8
Billable Status
Yes — Valid for Submission
Code Describes
Transfusion of Atidarsagene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8
Short Description
Transfuse Atidars Autotem in Central Vein, Perc, New Tech 8
Parent Code
XW1

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1SectionXNew Technology
2Body SystemWAnatomical Regions
3Operation1Transfusion
4BodyPart4Central Vein
5Approach3Percutaneous
6Device/Substance/TechnologyGAtidarsagene Autotemcel
7Qualifier8New Technology Group 8

In the ICD-10-PCS Alphabetic Index

These FY 2027 ICD-10-PCS Alphabetic Index entries lead to this code:

LENMELDY(tm)
Anatomy or device term that leads here
Omidubicel
Leads to this code's table
Autotransfusion
Leads to this code's table
Atidarsagene Autotemcel
Leads to this code's table
Betibeglogene Autotemcel
Leads to this code's table
Exagamglogene Autotemcel
Leads to this code's table
Mozafancogene Autotemcel
Leads to this code's table
Marnetegragene Autotemcel
Leads to this code's table
New Technology, Omidubicel
Leads to this code's table
Lovotibeglogene Autotemcel
Leads to this code's table
Transfusion, New Technology
Leads to this code's table
Administration, Blood products
Leads to this code's table
Convalescent Plasma (Nonautologous)
Leads to this code's table
Plasma, Convalescent (Nonautologous)
Leads to this code's table
New Technology, Atidarsagene Autotemcel
Leads to this code's table

To code new technology of the omidubicel, open the FY 2027 ICD-10-PCS Alphabetic Index at New Technology, then the subterm Omidubicel. The index leads to table XW1, where the approach, Device/Substance/Technology and qualifier values shown in the breakdown above complete the seven-character code XW143G8.

Browse the full ICD-10-PCS Alphabetic Index →

Clinical Classification (CCSR)

AHRQ groups this procedure code into these clinical categories.

ADM011
Administration and transfusion of bone marrow, stem cells, pancreatic islet cells, and t-cells
Clinical domain: Administration of Therapeutic Substances

Code History

Replaces previously assigned code(s):
  • 30243C0 — Transfuse Autol HSPC, Gene Mod in Central Vein, Perc

Similar Procedure Codes

Questions About XW143G8

Is XW143G8 a billable code?

Yes. This is a complete seven-character ICD-10-PCS code, specific enough to report Transfusion of Atidarsagene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8 on inpatient claims from October 1, 2026 through September 30, 2027.

What do the characters in XW143G8 mean?

The code breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 1 is the Operation (Transfusion); the 4th character 4 is the BodyPart (Central Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character G is the Device/Substance/Technology (Atidarsagene Autotemcel); the 7th character 8 is the Qualifier (New Technology Group 8).

What MS-DRG does XW143G8 group to?

On an inpatient stay, Transfusion of Atidarsagene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8 maps to MS-DRGs 016, 017, with relative weights from 3.3032 to 6.0136. The MS-DRG sets the fixed Medicare payment for the stay.